In a phase 1b study of an anti-TIM-3 antibody (MBG453) in combination with decitabine or azacitidine in patients with AML and high-risk MDS (NCT03066648), 69 patients with high risk-MDS or AML received MBG453 plus decitabine. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.